Prenatal prediction of spinal muscular atrophy


Abstract
Spinal muscular atrophy (SMA) is a common cause of inherited morbidity and mortality in childhood. The wide range of phenotypes in SMA, uncertainty regarding its mode of inheritance, and the suggestion of linkage heterogeneity have complicated the genetic counselling of parents of affected children. The locus responsible for autosomal recessive SMA has been mapped to 5q11.2–q13.3. The most likely order of loci is cen-D5S6-(SMA,D5S125)-(JK53CA1/2,DSS112)-DSS39-qter, with highly polymorphic loci being identified at JK53CA1/2 and DSS39. We describe linkage studies with another highly polymorphic locus, D5S127, that is closely linked to DSS39. This genetic map can be used as the basis for genetic counselling in families with autosomal recessive SMA. Appropriate allowance can be made for sporadic cases owing to non-inherited causes and for linkage heterogeneity or misdiagnoses.

The locus for autosomal recessive spinal muscular atrophy (SMA) has been mapped to the proximal long arm of human chromosome 5. The disease primarily affects the anterior horn cells of the spinal cord and motor cranial nerve nuclei, but nothing is known of the pathogenesis. Affected subjects generally present with one of three forms of the disease. The most severe type (type I, acute SMA or Werdnig-Hoffmann disease) is characterised by onset in the first six months of life, failure to sit, and usually death by the age of 2 years. An intermediate form (type II) has a later onset but the affected child never walks unaided. The prognosis in these cases is variable and depends on the degree to which the respiratory muscles are affected. In the comparatively mild form of the disease (type III, Kugelberg-Welander disease), affected subjects maintain independent ambulation. Allelic mutations at the SMA locus are thought to account for the variation in phenotype.

We have recently localised SMA in relation to highly polymorphic loci at 5q11.2–q13.3 in families with two or more affected persons. The order of loci (and sex averaged recombination fractions) are cen-D5S6-(0.02)-DSS125-(0.04)-(JK53CA1/2,DSS112)-(0.04)-DSS39-qter. No recombination was observed between SMA and DSS125. The closest markers known to flank SMA are DSS6 and (JK53CA1/2,DSS112). The distance between these loci is only 6 cM.

In view of this precise localisation of SMA, it should be possible to offer couples who have had an affected child prenatal diagnosis during subsequent pregnancies. However, there are a number of issues which confound the direct application of this genetic map to the counselling of affected families. First, SMA is a clinically heterogeneous disorder. Although the clinical features are usually consistent among the affected subjects in a pedigree, some reported pedigrees show wide variation in the severity of muscle weakness. In the absence of a clinical sign or investigation specific for SMA the wide variation in phenotype raises the possibility of misdiagnosis, particularly when evaluating an isolated case.

Second, a comprehensive genetic model of SMA has not been described. It is generally agreed that severe SMA is autosomal recessive, but a number of studies have indicated that the segregation ratio in pedigrees with intermediate or mild SMA is significantly less than the value of 0:25 expected for an autosomal recessive disorder. It is not known whether this distortion of the segregation ratio reflects misdiagnoses, a high mutation rate, or a complex genetic model. Conversely, some pedigrees have an unexpectedly high frequency of cases among second degree relatives which could be explained by a three allele single locus model.

Third, evidence has been presented indicating genetic heterogeneity among pedigrees with SMA of all types. The majority of families studied indicated linkage of SMA to DSS6, but approximately 15% were not linked to 5q loci. Tests of linkage heterogeneity do not distinguish between genetic heterogeneity owing to a second disease locus or apparent heterogeneity owing to the misclassification of some persons or families. A number of the unlinked families have been clinically reviewed, and the original diagnosis of SMA has been refuted. Although there may be no linkage heterogeneity among a tightly defined group of families with SMA, the possibility of misdiagnosis remains when counselling an individual family.

In this paper we describe the genetic localisation of another highly polymorphic locus in relation to SMA, and present our approach to prenatal diagnosis in SMA families.

Methods
Restriction fragment length polymorphisms (RFLPs) have been documented at DSS6, DSS112, and DSS39. The other polymorphisms used in this study were (CA), dinucleotide repeats. Details of the polymorphisms, primers, and PCR conditions are summarised in tables 1 and 2.
Table 1  Polymorphic loci closely linked to SMA.

<table>
<thead>
<tr>
<th>D.S.S.</th>
<th>Probe name</th>
<th>Type</th>
<th>PIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>D.S.S.6</td>
<td>pM4</td>
<td>BamH1</td>
<td>0-51</td>
</tr>
<tr>
<td>D.S.S.125</td>
<td>pM4</td>
<td>C9</td>
<td>0-36</td>
</tr>
<tr>
<td>D.S.S.112</td>
<td>pM4</td>
<td>HgiI</td>
<td>0-37</td>
</tr>
<tr>
<td>D.S.S.39</td>
<td>p105-153RA</td>
<td>MspI</td>
<td>0-39</td>
</tr>
</tbody>
</table>


Linkage analysis of D.S.S.127 in relation to SMA and other loci was performed using genotypes from 31 pedigrees with two or more subjects having severe, intermediate, or mild SMA. The criteria for including these families in the study are published elsewhere.2 For this set of families, SMA was assumed to be a monogenic autosomal recessive disorder. The odds in favour of an autosomal recessive versus three allele model21 for this data set were 10:1; the genetic localisation of SMA was the same under each model. The mutant allele frequency was taken to be 0.006, the penetrance 1-0, and the mutation rate zero.1

In families presenting for genetic risk counselling the diagnosis in the proband was established using defined criteria.4 The appropriate choice of genetic model is discussed below. All linkage analyses were performed using version 5-1 of the LINKAGE package of computer programs21 which makes no provision for interference when analysing three or more loci.

Results

Evaluation of the four dinucleotide repeat polymorphisms can be simplified by combining the PCR reactions for D.S.S.125/D.S.S.127. These four polymorphisms can also be determined from dried blood spots. Examples of the various polymorphisms at loci close to SMA are shown in fig 1.

Two point lod scores of D.S.S.127 and the other loci are listed in table 3, and indicate that D.S.S.127 is close to D.S.S.39. The loci D.S.S.127 and D.S.S.39 have been co-localised to two yeast artificial chromosomes and lie within 350 kb of one another (M J Francis, K E Davies, unpublished observations). Thus, the order of loci at 5q11-q13 is cen-D.S.S.6-(SMA,D.S.S.125)- (J.K.S.C.A.1/2,D.S.S.112)-(D.S.S.127,D.S.S.39)-ter.

Prenatal counselling: case studies

Family 1. Severe SMA (fig 2)

The proband presented at 4 months of age with delayed motor milestones and a paucity of spontaneous movement. His assessment was complicated by severe aspiration pneumonia, but a muscle biopsy was consistent with the diagnosis of SMA. He never sat unaided and died within the first year of life. The proband's parents then had monozygotic twin girls who also had severe hypotonia and died within the first year of life. There were no other sibs and there was no family history of muscle weakness. The parents presented during the third pregnancy requesting prenatal diagnosis.

The mode of inheritance of SMA was assumed to be autosomal recessive. The prior probability of the disease locus being linked to 5q loci in this family was arbitrarily assumed to be 0-95, thereby making a 5% allowance for either misdiagnosis or genetic heterogeneity. By using Bayesian analysis and the genotypes of the parents and affected children,22 the posterior probability of the family being of the linked type was 99%.

After chorionic villus sampling at 10 weeks' gestation, the fetal genotype was determined at D.S.S.6 (probe pM4) and D.S.S.39 (probe p105-153RA). Assuming the family to be of the linked type, the risk of the fetus being affected was estimated with SMA located at four different points within the interval D.S.S.6- (J.K.S.C.A.1/2,D.S.S.112).24 The risk interval was 1 to 10%. Assuming the family to be of the linked type, the risk to the fetus would be 25%. These two risk estimates were weighted according to the posterior probabilities that the family was of the linked versus unlinked type. The final risk interval for the fetus being affected was 2 to 11%. The pregnancy spontaneously miscarried at 22 weeks' gestation.

Family 2. Severe SMA (fig 2)

The proband was diagnosed at 4 months of age. He had extreme hypotonia, clinically obvious fasciculation, and an EMG and muscle biopsy consistent with a diagnosis of SMA. His condition rapidly deteriorated and he died before his first birthday. He had no sibs and there was no family history of muscle weakness. The proband's parents then presented during the next pregnancy requesting prenatal diagnosis.

Table 2  PCR conditions for detecting dinucleotide repeat polymorphisms.

<table>
<thead>
<tr>
<th>Locus</th>
<th>Primers</th>
<th>Temp</th>
<th>MgCl₂ (mmol/l)</th>
<th>Time (minutes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D.S.S.125</td>
<td>5'-AAAGAGACCTCCCATGTTGTTG-3'</td>
<td>62°C</td>
<td>1.0</td>
<td>120</td>
</tr>
<tr>
<td></td>
<td>5'-TAGAAAATACTACAGTCCTGTTG-3'</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J.K.S.C.A.1/2</td>
<td>5'-GGCTGCGCTCTTGTGCTACCTG-3'</td>
<td>54°C</td>
<td>1.5</td>
<td>240</td>
</tr>
<tr>
<td>D.S.S.39</td>
<td>5'-CGATGTTGTTGTTGTTCCAG-3'</td>
<td>60°C</td>
<td>1.0</td>
<td>120</td>
</tr>
<tr>
<td>D.S.S.127</td>
<td>5'-CTGGGTTTCAGATGCTCACTCT-3'</td>
<td>62°C</td>
<td>1.0</td>
<td>120</td>
</tr>
</tbody>
</table>

PCR conditions for a 6 μl reaction: 50 nmol/l KCl, 10 nmol/l tris-HCl, 0.01% glycerol, 1 pmol of each primer, 200 pmol/l dCTP, dGTP, dTPP, 25 pmol/l dATP, 0.2 μl [35S]dATP (>1000 Ci/mmol, Amer sham), 0-15 units Taq DNA polymerase (Perkin-Elmer), 2-10 ng of template DNA, and the specified concentration of MgCl₂. The reactions were denatured at 94°C for one minute, annealed for one minute at the specified temperature, and extended for one minute (extension step may be omitted for J.K.S.C.A.1/2) for 35 cycles, with a final extension at 72°C for four minutes. Half the reaction volume was electrophoresed in a 6% denaturing polyacrylamide gel (with formamide loading buffer) at 50 W for the specified time.
The mode of inheritance was assumed to be autosomal recessive. The prior probability that the family was of the linked type was 95%. As there was only one child in the sibship, this probability could not be altered by evaluation of genotypes within the family.

After chorionic villus sampling at 12 weeks' gestation, the fetal genotype was determined at D5S6, JK53CA1/2, D5S127, and D5S39. Genotyping at D5S125 was not successful. Assuming the family to be of the linked type, the risk of the fetus being affected was then estimated for four locations of SMA within the interval D5S6-(JK53CA1/2,D5S112). The risk was greater than 99%. Assuming the family to be of the unlinked type, the risk of the fetus being affected was 25%. The final weighted risk of the fetus being affected was 96%. The pregnancy was terminated.

**Family 3. Intermediate SMA** (fig 2)

The proband was diagnosed at 17 months of age. His development had been normal during the first few months of life, but weakness was noted from the age of 9 months. He sat unaided at 11 months, but never stood or walked alone. The clinical findings, muscle ultrasound, and a muscle biopsy were consistent with a diagnosis of intermediate SMA. The proband's parents presented during the second pregnancy requesting prenatal diagnosis.

The empirical recurrence risk in this situation is approximately 20%, which presumably reflects autosomal recessive inheritance together with a proportion of misdiagnoses, new mutations, or non-genetic causes. If the diagnosis of SMA is correct, the penetrance of autosomal recessive SMA is 1.0, and autosomal dominant and X linked forms of the disease have been excluded, the prior probability of an isolated case of intermediate SMA being autosomal recessive is approximately 80%, the remainder of the risk being attributable to non-inherited causes. Although these assumptions appear demanding, the fact that linkage heterogeneity has not been documented in...
familial intermediate SMA despite assuming complete penetrance provides support for this line of reasoning. As the proband did not have any sibs, the prior probability could not be altered by evaluation of genotypes within the family. After chorionic villus sampling at 10 weeks' gestation, the fetal genotypes at DSS6 and DSS39 were determined. Assuming that the disease locus in this family was autosomal recessive and linked to 5q loci, the risk of the fetus being affected was less than 2%. Because the prior probability of the disease locus being autosomal recessive but unlinked to 5q loci is small relative to the prior probability of the disease being non-inherited, the recurrence risk attributable to an autosomal recessive unlinked locus was ignored. The prior probability of intermediate SMA being non-inherited in this family is approximately 20%; the recurrence risk here was arbitrarily taken to be 1%. Therefore the final weighted risk of the fetus having intermediate SMA was approximately 1.8%. The pregnancy proceeded to a normal delivery at term; in the immediate postnatal period the baby appeared normal.

**Family 4. Intermediate SMA (fig 2)**
The proband was noted to be hypotonic at 5 months of age. He sat unaided but unsteadily at 12 months of age; stable sitting was achieved at 18 months of age. He never stood or walked unaided. The clinical findings, EMG, and muscle biopsy were consistent with a diagnosis of intermediate SMA. He had two unaffected sisters.

Although the parents have not presented requesting prenatal diagnosis, the following protocol would be appropriate. The prior probability that the disease is autosomal recessive is 80%. The proband and his two sisters had the same genotypes at DSS6 and DSS39, suggesting that SMA was not autosomal recessive in this family. On the basis of the genotypes at DSS6 and DSS39, the likelihood of the disease being a new mutation rather than autosomal recessive was 0.71. (The relative likelihood of observing these genotypes was calculated assuming SMA to be autosomal recessive and located at DSS12 (versus all loci being unlinked). The proband was then coded as normal, thereby mimicking a new mutation, and the relative likelihood recalculated. The difference in the two relative likelihoods was the likelihood that the disease was autosomal recessive rather than non-inherited.) Therefore the posterior probability that the disease was autosomal recessive was 62%. In a subsequent pregnancy the risk of the fetus being affected could be calculated assuming autosomal recessive inheritance and using the fetal genotypes at DSS6 and DSS39. If the proband had a non-inherited form of SMA the recurrence risk would be 1%. The two risks could be weighted according to the posterior probabilities that the disease was autosomal recessive or non-inherited in this family.

**Discussion**
The disease locus in families with autosomal recessive SMA has been mapped to 5q11-q13 in pedigrees having two or more affected members. We have genetically mapped a series of highly polymorphic loci that are very close to SMA. The order of loci is cen-DSS6-SMA-DSS12-JK53CA1/2-DSS112-DSS127-DSS39-qter. The genotypes at all loci other than DSS6 and DSS112 can be determined from dried blood spots, and hence genotypic information can be obtained from the Guthrie card of a child who has died. Therefore, the stage should be set for the provision of prompt and accurate prenatal diagnosis of this often distressing disease.

The problems of potential misdiagnosis, uncertain mode of inheritance, and linkage heterogeneity in spinal muscular atrophy should make one cautious in applying this genetic map in a counselling situation. Nevertheless, it is possible to use this genetic map as the basis for prenatal diagnosis. Our current approach to prenatal testing of autosomal recessive SMA is summarised in table 4.

We would emphasise that any approach to prenatal diagnosis must be based on a correct diagnosis in the proband. Because of the wide phenotypic variation in SMA, the diagnosis is not always straightforward. Where there is

---

**Table 4 Prenatal diagnostic protocol for autosomal recessive SMA.**

<table>
<thead>
<tr>
<th>Diagnosis in proband</th>
<th>Sibs</th>
<th>Course of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1 Severe SMA</td>
<td>None</td>
<td>AR* inheritance. Probability that the disease locus is linked to 5q is 95%. Estimate fetal risk of being affected for locations of SMA in DSS6-JK53CA1/2-DSS112. If the disease locus is unlinked, 25%. Final risk is weighted mean of risk if disease locus is linked and risk if unlinked.</td>
</tr>
<tr>
<td>1-2 Intermediate SMA</td>
<td>Any number</td>
<td>AR inheritance. Use family genotypes and Bayesian analysis to determine posterior probability that family is of the linked type. Then proceed as in protocol 1.1.</td>
</tr>
<tr>
<td>2-1 Intermediate SMA</td>
<td>None</td>
<td>Prior probability that disease is AR and linked to 5q is 80%. Ignore possibility of AR inheritance unlinked to 5q. Estimate fetal risk of being affected for locations of SMA in DSS6-JK53CA1/2-DSS112. Assume recurrence risk in sporadic cases is 1%. Final risk is weighted mean of risk if AR and risk if sporadic.</td>
</tr>
<tr>
<td>2-2 Mild SMA</td>
<td>Any number</td>
<td>Prior probability that disease is AR and linked to 5q is 80%. Use family genotypes and Bayesian analysis to determine posterior probability that disease is AR. Then proceed as for protocol 2.1.</td>
</tr>
<tr>
<td>2-3</td>
<td>None</td>
<td>Prior probability that disease is AR is 40%. Proceed as for protocol 2.1.</td>
</tr>
<tr>
<td>2-4</td>
<td>Any number</td>
<td>Prior probability that disease is AR is 40%. Proceed as for protocol 2.2.</td>
</tr>
</tbody>
</table>

*Autosomal dominant SMA, X linked SMA, the various distal SMA syndromes, and X linked muscular dystrophies must be excluded before considering prenatal diagnosis. AR = autosomal recessive.

†AR = autosomal recessive.

‡The genetic map is cen-DSS6-[0-02]-DSS12-[0-04]-JK53CA1/2-DSS112-[0-04]-DSS127-DSS39-qter, with SMA located between DSS6 and JK53CA1/2-DSS112.
Prenatal prediction of spinal muscular atrophy

doubt, appropriate consultation should be obtained before proceeding with prenatal diagnosis. It should also be noted that the disease locus in autosomal dominant SMA is not localised to 5q11-q13.20 Although we have not documented linkage heterogeneity in our set of 31 pedigrees with two or more affected subjects, we consider it prudent to assume some degree of linkage heterogeneity (or possible misdiagnoses) when estimating risks in small families with severe SMA. Although it is arguable whether the risk in an unlinked pedigree should be 25% (that is, assuming autosomal recessive inheritance) or zero, in practice it makes little difference to the risk figure.

We have no experience of prenatal diagnosis in families with mild SMA. The empirical recurrence risk is 6 to 10%.* (Empirical recurrence risk figures may be higher in some populations.*) This figure was derived from studies in the north of England and in London.) Making the same assumptions as outlined above for intermediate SMA (family 3), the prior probability of an isolated case of mild SMA being autosomal recessive is approximately 40%, the remainder of the risk being attributable to non-inherited causes. As before, these assumptions appear quite demanding, especially as the proportion of non-inherited cases seems relatively high. In support of these prior probabilities is the lack of linkage heterogeneity in families with mild SMA despite the assumption of complete penetrance. We would stress that the choice of prior probabilities is used simply to partition the recurrence risk into components which can be readily estimated for a family, and do not represent a complete genetic model of the disorder. On this basis prenatal diagnosis would be possible along the lines detailed for families with intermediate SMA.

When linkage analysis is used as the basis of prenatal diagnosis, genotypes should be determined at loci which flank the disease locus. The loci D5S6 and (JK353CA1/2,DSS12) lie 6 cM apart and flank SMA.8 RFLPs have been documented at D5S6 and DSS12 (table 1). As yet, a PCR based polymorphism has not been detected at D5S6 or at a locus tightly linked to it, and determination of the fetal genotype at DSS6 requires more placental tissue and time than determination of genotypes at other loci. If a family is uninformative at DSS6 there is no other locus that is highly informative, precisely mapped close to SMA, and centromeric to DSS6. Our current practice is to determine genotypes at DSS6, DSS125/DSS127 (a single PCR reaction), and JK353CA1/2. The dinucleotide repeat polymorphism at DSS39 is more difficult to interpret than the polymorphism at the tightly linked locus DSS127.

Ideally, a prenatal diagnostic protocol such as we describe should be audited to determine the frequency of incorrect diagnoses of the fetus. False negative diagnoses would be readily ascertained when a supposedly homozygous normal or heterozygous child developed symptoms. On three occasions we have concluded that a fetus would be at low risk of being affected with severe or intermediate SMA; one pregnancy miscarried (family 1), one baby appears normal in the neonatal period (family 3), and non-paternity was suspected in a third instance. Documented cases of false negative diagnoses should be reported promptly. False positive diagnoses are more of a problem. It is often difficult to obtain fetal tissues suitable for histopathological examination during a termination of pregnancy at 10 to 12 weeks' gestation. Even if such tissues were obtained, there are no recognised pathological features that are specific for SMA at this gestation.

A three allele model for SMA could have significant implications for prenatal diagnosis and counselling.13 According to this model, the alleles at SMA may be normal (+), mutant (−), or 'activator' (a) with allele frequencies of 0.8999, 0.0001, and 0.1000, respectively. Only the genotypes −/− and a/− result in the SMA phenotype. If this model is correct, one of the parents of an affected subject could have an a/a genotype. In this situation the recurrence risk would be 50%, and prenatal diagnosis based on an autosomal recessive model would be liable to error. It has been suggested that prenatal diagnosis in SMA be deferred until this is resolved. However, this approach is unnecessarily cautious. Under this model, the only joint parental genotype that could give a 50% recurrence risk in a sibship is +/−,a/a (assuming the parents are unaffected). All other parental genotype combinations would result in either no affected children in a recurrence risk of 25% in the sibship. The probability that an affected child have a joint genotype of +/−,a/a compared to genotype combinations with lower risks is only 10%. There would be insufficient information in a small pedigree to determine whether the two or three allele model is more likely to be correct and hence to weight risk figures derived under each model. In practice it may be worth calculating the relative likelihoods of the two versus three allele models when advising large pedigrees with affected second and third degree relatives. The risks estimated under each model could then be weighted according to the relative likelihoods.

We would like to thank Drs John Tolmie, Howard Hughes, and J Ignatius for referring families; Dr John Old for technical assistance with CVS samples; Dr Anthony Monaco for access to his YAC library; and Sue Clark for technical assistance. This work was funded by the Medical Research Council, the Muscular Dystrophy Association, USA, the Muscular Dystrophy Group of Great Britain and Northern Ireland, and the Nuffield Foundation.

Prenatal prediction of spinal muscular atrophy.

R J Daniels, G K Suthers, K E Morrison, N H Thomas, M J Francis, C G Mathew, S Loughlin, A Heiberg, D Wood and V Dubowitz

doi: 10.1136/jmg.29.3.165

Updated information and services can be found at:
http://jmg.bmj.com/content/29/3/165

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/